Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "BAL-Pharma"

409 News Found

Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules
Drug Approval | November 20, 2024

Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules

The product will be manufactured at Lupin’s Somerset facility in the US


Lupin launches Bumetanide Injection USP in US
News | November 20, 2024

Lupin launches Bumetanide Injection USP in US

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US


Indegene announces new Center in Hyderabad
Digitisation | November 20, 2024

Indegene announces new Center in Hyderabad

With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies


Lupin receives tentative approval from USFDA for Raltegravir Tablets
Drug Approval | November 09, 2024

Lupin receives tentative approval from USFDA for Raltegravir Tablets

This product will be manufactured at Lupin’s Nagpur facility in India


USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
Drug Approval | November 02, 2024

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature


Lupin to develop inhalers with near-zero global warming potential propellants
Sustainability | November 01, 2024

Lupin to develop inhalers with near-zero global warming potential propellants

Lupin's R&D teams are working on products with a near-zero global warming potential propellant


Lupin launches first generic of Pred Forte in US
News | October 16, 2024

Lupin launches first generic of Pred Forte in US

Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte


Wockhardt files fast-acting Insulin Aspart injection with DCGI
News | October 16, 2024

Wockhardt files fast-acting Insulin Aspart injection with DCGI

The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players


India’s emergence as a hub for affordable medicines is commendable: Dr. Jitendra Singh
News | October 10, 2024

India’s emergence as a hub for affordable medicines is commendable: Dr. Jitendra Singh

We now rank 3rd in pharmaceutical production by volume and 14th by value